Skip to main content
. 2016 May 20;24(15):839–854. doi: 10.1089/ars.2014.6128

FIG. 6.

FIG. 6.

The anti-GC activity of DATS in combination with DOC in relation to MT2A expression and NF-κB activation. (A) MTT assay monitoring the viability of BGC823 cells treated with 40 μM DATS, 10 nM DOC, and the combination (40 μM DATS +10 nM DOC) for 3 days. (B) Colony formation by BGC823 cells treated with DATS (40 μM) and/or DOC (10 nM) once a week for 4 weeks. Left panel: representative analysis of cell cycle distribution (C) and apoptosis (D) of BGC823 cells after treatment with DATS and/or DOC. Right panel: quantitation. (E) Western blotting of BGC823 cells upon indicated treatment. (F) Luciferase assay measuring NF-κB activity in BGC823 cells. BGC823 cells were transiently cotransfected with pNF-κB-Luc and pRL-TK, with or without pcDNA3.1-MT2A, for 24 h, and then were treated with DATS (40 μM) and/or DOC (10 nM) for another 12 h. Cells incubated with TNF-α serve as positive control. Relative luciferase activities were relative to luciferase activity in unstimulated cells. Data from at least three independent experiments are presented as the mean ± standard deviation, *p < 0.05, **p < 0.01 versus control. DOC, docetaxel; TNF-α, tumor necrosis factor-alpha.